Prasinezumab, a monoclonal antibody, is shown to reduce signs of motor deterioration in individuals with Parkinson’s disease (PD) who have rapidly progressing disease, as reported in an exploratory analysis of data from a large phase 2 clinical trial published in Nature Medicine.
This article was originally published on MedicalXpress.com
Whether you jog to keep fit or compete in marathons, the physically demanding sport of running can deplete the body of essential nutrients. During a race like a half-marathon, a runner’s metabolism — or ability […]
Fostering a rewarding and fulfilling relationship is no easy task. You and your partner are only human, and, as the saying goes, you are going to make mistakes. However, learning the common relationship mistakes and […]
In this article, we will introduce you to 12 incredibly effective foot massage techniques that will leave you feeling rejuvenated and relaxed. Foot massages aren’t just a luxury; they provide numerous health benefits, such as […]
© 2024 SimplyWell.ca